Maple Healthcare Center in Los Angeles, CA

Maple Healthcare Center is a medicare and medicaid certified nursing home in Los Angeles, California. It is located in Los Angeles county at 2625 Maple Ave., Los Angeles, California 90011. You can reach out to the office of Maple Healthcare Center via phone at (213) 747-6371. This skilled nursing facility has 59 federally certified beds with average occupancy rate of 85.25%. Its legal business name is United Convalescent Facilities, Inc. and has the following ownership type - For Profit - Individual.

Maple Healthcare Center (Medicare CCN 055036) is certified by CMS (Centers for Medicare & Medicaid Services) and participates in both medicare and medicaid program. This means if you are part of medicare or medicaid program, you may consider this nursing facility for your medical needs. It was first certified by CMS in 1974 (50 years certified) and the last quality survey was conducted in October, 2019.

Name	Maple Healthcare Center
Location	2625 Maple Ave., Los Angeles, California
Certified By	Medicare and Medicaid
No. of Certified Beds	59
Occupancy Rate	85.25%
Medicare ID (CCN)	055036
Legal Business Name	United Convalescent Facilities, Inc.
Ownership Type	For Profit - Individual

Nursing Homes may have multiple NPI numbers. We have found possible NPI number/s associated with Maple Healthcare Center from NPPES records by matching pattern on the basis of name, address, phone number etc. Please use this information accordingly.

NPI Number	1710972062
Organization Name	UNITED CONVALESCENT FACILITIES, INC.
Doing Business As	MAPLE HEALTHCARE CENTER
Address	2625 Maple Avenue, Los Angeles, CA 90011
Phone Number	213-747-6371

News Archive

Health industries: Changes could kill health reform bill

Insurers and pharmaceutical manufacturers are concerned that changes in a Senate bill could derail efforts — and their agreement — to overhaul the nation's health care system.

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Compulsive hoarding study could improve diagnosis and treatment of psychiatric disorders

A PET imaging study conducted at the UCLA Neuropsychiatric Institute indicates the neurobiology of America's estimated 1 million compulsive hoarders differs significantly from people with other obsessive-compulsive disorder (OCD) symptoms. The findings indicate that different medications could improve treatment success.

New data on Merck's VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

Read more Medical News

› Verified 4 days ago

Nursing homes vary in the quality of care and services they provide to their residents. The below quality ratings for Maple Healthcare Center are calculated from three sources - health inspection results, staffing data, and quality measure data. This information gives you an indication of the care Maple Healthcare Center give to their patients.

Ratings from Surveys (Inspections):
Ratings from Quality Measures:
Ratings from Staffing Data:
Overall Rating:

News Archive

Health industries: Changes could kill health reform bill

Insurers and pharmaceutical manufacturers are concerned that changes in a Senate bill could derail efforts — and their agreement — to overhaul the nation's health care system.

Paratek receives FDA QIDP designation for omadacycline to treat ABSSSI, CABP

Paratek Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated the Company's lead antibiotic candidate, omadacycline (formerly known as PTK 0796), as a Qualified Infectious Disease Product (QIDP) for both intravenous (IV) and oral formulations in the treatment of acute bacterial skin and skin structure infections (ABSSSI) and community-acquired bacterial pneumonia (CABP).

Compulsive hoarding study could improve diagnosis and treatment of psychiatric disorders

A PET imaging study conducted at the UCLA Neuropsychiatric Institute indicates the neurobiology of America's estimated 1 million compulsive hoarders differs significantly from people with other obsessive-compulsive disorder (OCD) symptoms. The findings indicate that different medications could improve treatment success.

New data on Merck's VICTRELIS for chronic HCV to be presented at EASL annual meeting

Merck, known as MSD outside of the United States and Canada, announced today that two analyses of VICTRELIS (boceprevir) and data from Phase II studies of two of Merck's investigational medicines for chronic hepatitis C virus (HCV) genotype 1, MK-5172 and vaniprevir (MK-7009), will be presented at the 2013 International Liver Congress (EASL) Annual Meeting.

Read more Medical News

› Verified 4 days ago

Number of Facility Reported Incidents	0
Number of Substantiated Complaints	0
Number of Fines	4
Total Amount of Fines in Dollars	$10491
Number of Payment Denials	0
Total Number of Penalties	4

The resident survey data of Maple Healthcare Center is compared against the national average with the color code indicators: Better than National Average Worse than National Average

Experience Measure	Provider	National Avg.
Percentage of long-stay residents whose need for help with daily activities has increased	6.15	14.46
Percentage of long-stay residents who lose too much weight	10.11	5.51
Percentage of low risk long-stay residents who lose control of their bowels or bladder	12.73	48.41
Percentage of long-stay residents with a catheter inserted and left in their bladder	0	1.79
Percentage of long-stay residents with a urinary tract infection	0	2.65
Percentage of long-stay residents who have depressive symptoms	56.9	5.05
Percentage of long-stay residents who were physically restrained	0	0.23
Percentage of long-stay residents experiencing one or more falls with major injury	1.51	3.36
Percentage of long-stay residents assessed and appropriately given the pneumococcal vaccine	100	93.87
Percentage of long-stay residents who received an antipsychotic medication	14.62	14.2
Percentage of short-stay residents assessed and appropriately given the pneumococcal vaccine	100	83.88
Percentage of short-stay residents who newly received an antipsychotic medication	0	1.79
Percentage of long-stay residents whose ability to move independently worsened	21.41	17.09
Percentage of long-stay residents who received an antianxiety or hypnotic medication	7.58	19.7
Percentage of high risk long-stay residents with pressure ulcers	12.33	7.32
Percentage of long-stay residents assessed and appropriately given the seasonal influenza vaccine	100	95.98